Investigational drug · Phase 3
Mexiletine granules for prolonged-release
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myotonic Dystrophy.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "Mexiletine granules for prolonged-release"
First trial start
2025
Feb 13, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Mexiletine granules for prolonged-release", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myotonic Dystrophy
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Mexiletine granules for prolonged-release" as an intervention, largest first.
- The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2Pivotal-lookingRecruiting
Lupin Ltd.Industry
NCT06523400 · 176 participants (planned) · Start Feb 13, 2025 · Primary completion Jun 2027
Drug: Mexiletine granules for prolonged-release oral suspension; Placebo · For: Myotonic Dystrophy
Sites: Leuven, Belgium; Aarhus, Denmark; München, Germany · 7 sites in all
- An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.Pivotal-lookingEnrolling by invitation
Lupin Ltd.Industry
NCT06549400 · 176 participants (planned) · Start Sep 12, 2025 · Primary completion May 29, 2028
Drug: Mexiletine granules for prolonged-release oral suspension · For: Myotonic Dystrophy
Sites: Leuven, Belgium; Aarhus, Denmark; München, Germany · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Myotonic Dystrophy
- Del-desiranAOC 1001Phase 33 trials
Avidity Biosciences, Inc. · DM1, Myotonic Dystrophy, Myotonic Dystrophy 1
- zeleciment basivarsenDYNE-101Phase 32 trials
Dyne Therapeutics · Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy
- SAR446268Phase 21 trial
Sanofi · Myotonic Dystrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.